Towards the phenotyping of soft tissue tumours by cell surface molecules.
This study is aimed at the characterization of soft tissue tumours (STT) by means of cell surface molecules. To achieve this, normal mesenchymal tissues were extensively examined for expression of leucocyte differentiation (CD) antigens and HLA molecules. The panel of antigens finally examined in STT comprised CD10, CD13, CD24, CD34, CD36, CD56, CD57, HLA-A,B,C, beta 2-microglobulin, HLA-DR, -DP, and -DQ and the HLA-D-associated invariant chain (Ii). STT were determined by conventional histomorphological and immunohistochemical criteria. The immunohistological analysis was based on serial frozen sections, one of which was used to demonstrate CD53 antigen. This very broadly distributed leuco/histiocyte-restricted antigen allowed for the distinction between the background of interstitial "stromal" cells and the neoplastic population. In some STT, the expression pattern of the cell surface molecules corresponded to that in their non-neoplastic counterparts. The majority of STT, however, showed considerable changes in the cell surface immunophenotype compared to their cells of origin. These alterations consisted mainly in an aberrant induction/neoexpression and, to a much lesser extent, in an aberrant down-regulation/loss of cell surface antigens. Nevertheless, some immunophenotype configurations are described which, for the time being, can be considered to be useful supplements in the differential diagnosis of this complex class of tumours. The data also indicate considerable changes in cell surface antigen expression occurring in the course of neoplastic transformation of mesenchymal cells. Detailed analysis of alterations in the functional repertoire of neoplastic mesenchymal cells might provide new insights into the biology of STT, possibly leading to new concepts for therapeutic intervention.
Mechtersheimer
G
G
Pathologisches Institut Universität Heidelberg, Federal Republic of Germany.
D015703:Antigens, CD / Q000032:analysis*; D018952:Antigens, CD34; D000943:Antigens, Differentiation / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000945:Antigens, Differentiation, T-Lymphocyte / Q000032:analysis; D000951:Antigens, Neoplasm / Q000032:analysis; D018826:CD13 Antigens; D051927:CD24 Antigen; D018955:CD36 Antigens; D019002:CD56 Antigen; D018959:CD57 Antigens; D006680:HLA Antigens / Q000032:analysis; D006801:Humans; D016130:Immunophenotyping; D008562:Membrane Glycoproteins; D015260:Neprilysin; D010641:Phenotype; D012983:Soft Tissue Neoplasms / Q000276:immunology* / Q000473:pathology; D060265:Tetraspanin 25; D001613:beta 2-Microglobulin / Q000032:analysis
D015703:Antigens, CD; D018952:Antigens, CD34; D000943:Antigens, Differentiation; D015214:Antigens, Differentiation, Myelomonocytic; D000945:Antigens, Differentiation, T-Lymphocyte; D000951:Antigens, Neoplasm; D051927:CD24 Antigen; C497889:CD24 protein, human; D018955:CD36 Antigens; C554894:CD53 protein, human; D019002:CD56 Antigen; D018959:CD57 Antigens; D006680:HLA Antigens; D008562:Membrane Glycoproteins; D060265:Tetraspanin 25; D001613:beta 2-Microglobulin; D018826:CD13 Antigens; D015260:Neprilysin